Back to Search
Start Over
Concurrent Accelerated Hyperfractionated Radiation Therapy and Carboplatin/etoposide in Patients With Malignant Glioma: Long-term break Results of A Phase II Study.
- Source :
- Journal of Neuro-Oncology; Jan2001, Vol. 51 Issue 2, p133-141, 9p
- Publication Year :
- 2001
-
Abstract
- Purpose: Feasibility, antitumor activity and toxicity of accelerated hyperfractionated radiation therapy (Acc Hfx RT) and concurrent carboplatin/etoposide (CBDCA/VP 16) chemotherapy were investigated in patients with malignant glioma. Material and methods: Seventy-nine patients with either glioblastoma multiforme (GBM) ( n = 61) or anaplastic astrocytome (AA) ( n = 18) entered into a phase II study on the use of Acc Hfx RT with 60 Gy in 40 fractions in 20 treatment days over 4 weeks and concurrent CBDCA, 200 mg/m<superscript>2</superscript>, and VP 16, 200 mg/m<superscript>2</superscript>, both given once weekly during the RT course. Results: The median survival time for all 79 patients was 14 months (11 and 44 months for GBM and AA patients, respectively), while the 2- and 4-year survival was respectively 33% and 11% for all patients, 13% and 1.6% for GBM patients, and 100% and 44% for AA patients ( p < 0.0001). The median time to progression for all patients was 12 months (9 and 40 months for GBM and AA, respectively), while the 2- and 4-year progression-free survival (PFS) was respectively 28% and 10% (all patients), 10% and 1.7% (GBM) and 89% and 39% (AA) ( p < 0.0001). Multivariate analysis showed that age, performance status, and preoperative size of tumor influenced survival in GBM. Only 5 (6%) patients experienced grade 3 leukopenia and 6 (8%) patients experienced grade 3 thrombocytopenia. No late RT-induced toxicity was observed to date. Conclusions: Although Acc Hfx RT/CBDCA + VP 16 was feasible and little toxic, it failed to improve survival/progression-free survival over that obtained with other currently used regimens. These results do not justify the investigation of this regimen in a phase III trial. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0167594X
- Volume :
- 51
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Neuro-Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 50212525
- Full Text :
- https://doi.org/10.1023/A:1010621400203